Read as much as you want on BostonGlobe.com, anywhere and anytime, for just 99¢.

Vertex CF drug cleared in Australia

Kalydeco’s the first drug for the underlying cause of CF in people with a particular mutation.

Kalydeco’s the first drug for the underlying cause of CF in people with a particular mutation.

Continue reading below

Cambridge-based Vertex Pharmaceuticals Inc.’s Kalydeco drug for cystic fibrosis was approved by Australian regulators. Kalydeco, cleared by US regulators in February 2012, targets the cause of the disease in about 4 percent of the US patient population — those with a specific genetic mutation — helping them produce mucus to absorb and digest food. Life-threatening CF affects about 70,000 people worldwide. In April, investors bid up Vertex shares to a record high after clinical data appeared to dramatically improve the prospects of Vertex’s plan to build a portfolio of CF drugs.

Loading comments...
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com